循环肿瘤DNA在肝细胞癌诊疗中的研究进展

doi:10.3760/cma.j.cn371439-20230722-00008

摘要/Abstract

摘要：

肝细胞癌（HCC）是我国发病率第4、死亡率第2的恶性肿瘤，晚期患者已失去手术治疗机会，生存期短，预后极差。组织病理活检是恶性肿瘤临床诊断的金标准，但组织病理活检不仅是有创性检查，而且获得的组织样本较少，不能反映肿瘤的异质性，也难以动态监测肿瘤的进展情况或治疗疗效。因此，寻找新的非侵入性策略以早期发现HCC并监测HCC疗效具有重要的临床意义。循环肿瘤DNA是无创的液体活检方法，取样简单且能动态监测肿瘤基因组学变化，在HCC的早期诊断、疗效监测以及预后评估中具有重要应用价值。

关键词: 癌，肝细胞, 循环肿瘤DNA, 早期诊断, 预后

Abstract:

Hepatocellular carcinoma （HCC） is malignant tumor with the fourth incidence rate and the second mortality rate in China, and patients with advanced stage have lost the chance of surgical treatment, short survival period and extremely poor prognosis. Histopathological biopsy is the gold standard for clinical diagnosis of malignant tumors, but histopathological biopsy is not only invasive, but also obtains fewer tissue samples, which does not reflect the heterogeneity of tumors, and makes it difficult to dynamically monitor the progression of tumors or the efficacy of treatment. Therefore, it is clinically important to find new non-invasive strategies for early detection of HCC and to monitor the efficacy of HCC. Circulating tumor DNA is a non-invasive liquid biopsy method with simple sampling and can dynamically monitor the genomic changes of tumors, which has great application value in early diagnosis, therapeutic efficacy monitoring, and prognostic evaluation of HCC.

Key words: Carcinoma， hepatocellular, Circulating tumor DNA, Early diagnosis, Prognosis

黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.

Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.

参考文献 52

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	World Health Organization. GLOBOCAN 2020[EB/OL]. (2020-10-01)[2023-06-05]. http://gco.iarc.fr/today.
[3]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X. pmid: 29653628
[4]	Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718.e1. DOI: 10.1053/j.gastro.2018.01.064. pmid: 29425931
[5]	Janiszewska M. The microcosmos of intratumor heterogeneity: the space-time of cancer evolution[J]. Oncogene, 2020, 39(10): 2031-2039. DOI: 10.1038/s41388-019-1127-5. pmid: 31784650
[6]	Kaseb AO, Sánchez NS, Sen S, et al. Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA[J]. Clin Cancer Res, 2019, 25(20): 6107-6118. DOI: 10.1158/1078-0432.CCR-18-3341. pmid: 31363003
[7]	Temraz S, Nasr R, Mukherji D, et al. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma[J]. Expert Rev Mol Diagn, 2022, 22(5): 507-518. DOI: 10.1080/14737159.2022.2094706.
[8]	Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis[J]. Sci Transl Med, 2018, 10(466): eaat4921. DOI: 10.1126/scitranslmed.aat4921.
[9]	Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients[J]. Int J Mol Sci, 2013, 14(9): 18925-18958. DOI: 10.3390/ijms140918925. pmid: 24065096
[10]	Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer[J]. Chin J Cancer, 2016, 35: 36. DOI: 10.1186/s40880-016-0092-4. pmid: 27056366
[11]	Zhang BO, Xu CW, Shao Y, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation[J]. Exp Ther Med, 2015, 9(4): 1383-1388. DOI:10.3892/etm.2015.2221. pmid: 25780439
[12]	Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequen-cing of plasma DNA[J]. Sci Transl Med, 2012, 4(136): 136ra68. DOI:10.1126/scitranslmed.3003726.
[13]	Imperial R, Nazer M, Ahmed Z, et al. Matched whole-genome sequencing (WGS) and whole-exome sequencing (WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis: complementary modalities in clinical practice[J]. Cancers (Basel), 2019, 11(9): 1399. DOI: 10.3390/cancers11091399.
[14]	McGuire AL, Caulfield T, Cho MK. Research ethics and the challenge of whole-genome sequencing[J]. Nat Rev Genet, 2008, 9(2): 152-156. DOI:10.1038/nrg2302. pmid: 18087293
[15]	Cai Z, Chen G, Zeng Y, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(17): 5284-5294. DOI: 10.1158/1078-0432.CCR-18-3477. pmid: 31217202
[16]	Zhang Z, Chen P, Xie H, et al. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis[J]. Cancer Med, 2020, 9(4): 1349-1364. DOI: 10.1002/cam4.2799.
[17]	Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-930. DOI: 10.1126/science.aar3247. pmid: 29348365
[18]	Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J]. Nat Commun, 2020, 11(1): 3475. DOI: 10.1038/s41467-020-17316-z. pmid: 32694610
[19]	Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12): 2195-2205. DOI: 10.1136/gutjnl-2019-318882. pmid: 31358576
[20]	Nakatsuka T, Nakagawa H, Hayata Y, et al. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma[J]. J Gastroenterol, 2021, 56(5): 456-469. DOI: 10.1007/s00535-021-01773-4. pmid: 33712873
[21]	Hirai M, Kinugasa H, Nouso K, et al. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA[J]. J Gastroenterol Hepatol, 2021, 36(4): 1118-1125. DOI: 10.1111/jgh.15227.
[22]	Sefrioui D, Verdier V, Savoye-Collet C, et al. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization[J]. Int J Cancer, 2022, 150(3): 532-541. DOI: 10.1002/ijc.33829.
[23]	Cai ZX, Chen G, Zeng YY, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985. DOI: 10.1002/ijc.30798.
[24]	Park S, Lee EJ, Rim CH, et al. Plasma cell-free DNA as a pre-dictive marker after radiotherapy for hepatocellular carcinoma[J]. Yonsei Med J, 2018, 59(4): 470-479. DOI: 10.3349/ymj.2018.59.4.470.
[25]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. pmid: 29307467
[26]	Vogel A, Cervantes A, Chau I, et al. Correction to: "Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up"[J]. Ann Oncol, 2019, 30(5): 871-873. DOI: 10.1093/annonc/mdy510. pmid: 30715202
[27]	Xie DY, Zhu K, Ren ZG, et al. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2023, 12(2): 216-228. DOI: 10.21037/hbsn-22-469.
[28]	Wang J, Huang A, Wang YP, et al. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma[J]. Ann Transl Med, 2020, 8(5): 237. DOI: 10.21037/atm.2019.12.154. pmid: 32309384
[29]	Liu Z, Zhang Y, Shi C, et al. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma[J]. J Transl Med, 2021, 19(1): 5. DOI: 10.1186/s12967-020-02697-y. pmid: 33407585
[30]	Casak SJ, Donoghue M, Fashoyin-Aje L, et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma[J]. Clin Cancer Res, 2021, 27(7): 1836-1841. DOI: 10.1158/1078-0432.CCR-20-3407. pmid: 33139264
[31]	Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database[J]. JAMA, 2019, 321(14): 1391-1399. DOI: 10.1001/jama.2019.3241. pmid: 30964529
[32]	Jensen TJ, Goodman AM, Kato S, et al. Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients[J]. Mol Cancer Ther, 2019, 18(2): 448-458. DOI: 10.1158/1535-7163.MCT-18-0535. pmid: 30523049
[33]	Zhao W, Qiu L, Liu H, et al. Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer[J]. J Gastrointest Oncol, 2020, 11(5): 1065-1077. DOI: 10.21037/jgo-20-409. pmid: 33209498
[34]	Luke JJ, Bao R, Sweis RF, et al. Wnt/β-catenin pathway activation correlates with immune exclusion across human cancers[J]. Clin Cancer Res, 2019, 25(10): 3074-3083. DOI: 10.1158/1078-0432.CCR-18-1942. pmid: 30635339
[35]	Harding JJ, Nandakumar S, Armenia J, et al. Prospective genoty-ping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25(7): 2116-2126. DOI: 10.1158/1078-0432.CCR-18-2293. pmid: 30373752
[36]	Kwee SA, Tiirikainen M. Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers[J]. Hepatoma Res, 2021, 7: 8. DOI: 10.20517/2394-5079.2020.124.
[37]	Oversoe SK, Clement MS, Weber B, et al. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 376. DOI: 10.1186/s12885-021-08103-0. pmid: 33827453
[38]	von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma[J]. Oncogene, 2021, 40(1): 140-151. DOI: 10.1038/s41388-020-01519-1. pmid: 33097857
[39]	Ikeda S, Tsigelny IF, Skjevik ÅA, et al. Next-generation sequen-cing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma[J]. Oncologist, 2018, 23(5): 586-593. DOI: 10.1634/theoncologist.2017-0479.
[40]	Galle E, Thienpont B, Cappuyns S, et al. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer[J]. Clin Epigenetics, 2020, 12(1): 27. DOI: 10.1186/s13148-020-0821-z. pmid: 32059745
[41]	Ng CKY, Di Costanzo GG, Tosti N, et al. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study[J]. Ann Oncol, 2018, 29(5): 1286-1291. DOI: 10.1093/annonc/mdy083. pmid: 29509837
[42]	Alunni-Fabbroni M, Rönsch K, Huber T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial[J]. J Transl Med, 2019, 17(1): 328. DOI: 10.1186/s12967-019-2079-9. pmid: 31570105
[43]	Long G, Fang T, Su W, et al. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma[J]. Scand J Gastroenterol, 2020, 55(12): 1441-1446. DOI: 10.1080/00365521.2020.1839127.
[44]	An Y, Guan Y, Xu Y, et al. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma[J]. Am J Transl Res, 2019, 11(10): 6462-6474. pmid: 31737198
[45]	Li J, Jiang W, Wei J, et al. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors[J]. J Transl Med, 2020, 18(1): 293. DOI: 10.1186/s12967-020-02449-y. pmid: 32738923
[46]	Kim SS, Eun JW, Choi JH, et al. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma[J]. Sci Rep, 2020, 10(1): 17862. DOI: 10.1038/s41598-020-74494-y. pmid: 33082400
[47]	Hirai M, Kinugasa H, Nouso K, et al. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA[J]. J Gastroenterol Hepatol, 2021, 36(4): 1118-1125. DOI: 10.1111/jgh.15227.
[48]	Shen T, Li SF, Wang JL, et al. TP53 R249S mutation detected in circulating tumour DNA is associated with prognosis of hepatocellular carcinoma patients with or without hepatectomy[J]. Liver Int, 2020, 40(11): 2834-2847. DOI: 10.1111/liv.14581.
[49]	Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6): 579-586. DOI: 10.1200/JCO.2012.45.2011. pmid: 24449238
[50]	Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018, 563(7732): 579-583. DOI: 10.1038/s41586-018-0703-0.
[51]	Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019, 570(7761): 385-389. DOI: 10.1038/s41586-019-1272-6.
[52]	Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA[J]. BMC Cancer, 2019, 19(1): 832. DOI: 10.1186/s12885-019-6003-8. pmid: 31443703